Working… Menu

Study to Assess Immune Function and MRI Disease Activity in RRMS Patients When Switching From Natalizumab to Gilenya (ToFingo2)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT02325440
Recruitment Status : Unknown
Verified December 2014 by University Hospital Muenster.
Recruitment status was:  Recruiting
First Posted : December 25, 2014
Last Update Posted : December 25, 2014
Information provided by (Responsible Party):
University Hospital Muenster